For example, the phase III LIBRETTO-431 trial demonstrated selpercatinib significantly increased PFS over standard care for RET-positive NSCLC (24.8 vs. 11.2 months; HR 0.46; p < 0.001) [245]. This evidence concerns the gene RET and non-small cell lung carcinoma.